ТИРОНЕТ – все о щитовидной железе Для специалистов Журнал Тиронет 2013 год № 2
Комбинированная терапия L-T4 + L-T3 в лечении гипотиреоза
Бирте Нюгорд и Ганс Перрилд
Под редакцией В.В. Фадеева
Литература
Endocrinol Metab 2007; 92(8):3122-3127.
1. Pedersen IB, Laurberg P, Knudsen N et al. An increased incidence of overt hypothyroidism after iodine fortification of salt in Denmark: a prospective population study. J Clin
2. Vanderpump MP, Tunbridge WM, French JM et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol
(Oxf) 1995; 43(1):55-68.
3. Cooper DS, Biondi B. Subclinical thyroid disease. Lancet 2012; 379(9821):1142-1154.
4. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on ‘adequate’ doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf) 2002; 57(5):577-585.
5. Wekking EM, Appelhof BC, Fliers E et al. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur J Endocrinol 2005; 153(6):747-753.
6. Petersen K, Bengtsson C, Lapidus L, Lindstedt G, Nystrom E. Morbidity, mortality, and quality of life for patients treated with levothyroxine. Arch Intern Med 1990; 150(10):2077-2081.
7. Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP. 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur Thyroid J 2012; 1:55-71.
8. Pop VJ, Maartens LH, Leusink G et al. Are autoimmune thyroid dysfunction and depression related? J Clin Endocrinol Metab 1998; 83(9):3194-3197.
9. Ott J, Promberger R, Kober F et al. Hashimoto’s thyroiditis affects symptom load and quality of life unrelated to hypothyroidism: a prospective case-control study in women undergoing thyroidectomy for benign goiter. Thyroid 2011; 21(2):161-167.
10. Watt T, Hegedus L, Bjorner JB et al. Is Thyroid Autoimmunity per se a Determinant of Quality of Life in Patients with Autoimmune Hypothyroidism? Eur Thyroid J 2012; 1:186-192.
11. Somers EC, Thomas SL, Smeeth L, Hall AJ. Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder? Am J Epidemiol 2009; 169(6):749-755.
12. Weetman AP. Diseases associated with thyroid autoimmunity: explanations for the expanding spectrum. Clin Endocrinol (Oxf) 2011; 74(4):411-418.
13. Weetman AP. Whose thyroid hormone replacement is it anyway? Clin Endocrinol (Oxf) 2006; 64(3):231-233.
14. Ladenson PW. Psychological wellbeing in patients. Clin Endocrinol (Oxf) 2002; 57(5):575-576.
15. Perrild H, Knudsen N, Bjergved L et al. OP15 Mental vulnerability ia high in previously treated hyper and hypothyroidism. European thyroid Journal 2012; 1(S1):80.
16. Pilo A, Iervasi G, Vitek F, Ferdeghini M, Cazzuola F, Bianchi R. Thyroidal and peripheral production of 3,5,3’-triiodothyronine in humans by multicompartmental analysis. Am J Physiol 1990; 258(4 Pt 1):E715-E726.
17. Kaplan MM, Yaskoski KA. Phenolic and tyrosyl ring deiodination of iodothyronines in rat brain homogenates. J Clin Invest 1980; 66(3):551-562.
18. van DJ, Roelfsema F, van der Heide D. Concentrations of thyroxine and 3,5,3’-triiodothyronine at 34 different sites in euthyroid rats as determined by an isotopic equilibrium technique. Endocrinology 1985; 117(3):1201-1208.
19. Escobar-Morreale HF, Obregon MJ, Escobar del RF, Morreale de EG. Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. J Clin Invest 1995; 96(6):2828-2838.
20. Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP. Oppenheimer JH. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. Role of triiodothyronine in pituitary feedback in humans. N Engl J Med 1987; 316(13):764-770.
21. Jonklaas J, Davidson B, Bhagat S, Soldin SJ. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA 2008; 299(7):769-777.
22. Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ, Jr. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999; 340(6):424-429.
23. Grozinsky-Glasberg S, Fraser A, Nahshoni E, Weizman A, Leibovici L. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 2006; 91(7):2592-2599.
24. Saravanan P, Simmons DJ, Greenwood R, Peters TJ, Dayan CM. Partial substitution of thyroxine (T4) with triiodothyronine in patients on T4 replacement therapy: results of a large community-based randomized controlled trial. J Clin Endocrinol Metab 2005; 90(2):805-812.
25. Appelhof BC, Fliers E, Wekking EM et al. Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab 2005; 90(5):2666-2674.
26. Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange AJ, Jr. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999; 340(6):424-429.
27. Walsh JP, Shiels L, Lim EM et al. Combined thyroxine/ liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism. J Clin Endocrinol Metab 2003; 88(10):4543-4550.
28. Siegmund W, Spieker K, Weike AI et al. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf) 2004; 60(6):750-757.
29. Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. JAMA 2003; 290(22):2952-2958.
30. Sawka AM, Gerstein HC, Marriott MJ, MacQueen GM, Joffe RT. Does a combination regimen of thyroxine (T4) and 3,5,3’-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial. J Clin Endocrinol Metab 2003; 88(10):4551-4555.
31. Rodriguez T, Lavis VR, Meininger JC, Kapadia AS, Stafford LF. Substitution of liothyronine at a 1:5 ratio for a portion of levothyroxine: effect on fatigue, symptoms of depression, and working memory versus treatment with levothyroxine alone. Endocr Pract 2005; 11(4):223-233.
32. Saravanan P, Simmons DJ, Greenwood R, Peters TJ, Dayan CM. Partial substitution of thyroxine (T4) with triiodothyronine in patients on T4 replacement therapy: results of a large community-based randomized controlled trial. J Clin Endocrinol Metab 2005; 90(2):805-812.
33. levitt J, Silverberg J. T4 plus T3 for hypothyroidism: a double-blind comparison with usual T4. Proc of 74th Annual meeting of the American Thyroid Association, Los Angeles CA 2002; 1:1. 10 Thyroid International
34. Siegmund W, Spieker K, Weike AI et al. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf) 2004; 60(6): 750-757.
35. Escobar-Morreale HF, Botella-Carretero JI, Gomez-Bueno M, Galan JM, Barrios V, Sancho J. Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med 2005; 142(6):412-424.
36. Bunevicius R, Jakubonien N, Jurkevicius R, Cernicat J, Lasas L, Prange AJ, Jr. Thyroxine vs thyroxine plus triiodothyronine in treatment of hypothyroidism after thyroidectomy for Graves’ disease. Endocrine 2002; 18(2):129-133
37. Smith R, Taylor S, massey J. Controlled clinical trial of combined triiodothyronine and thyroxine in the treatment of hypothyroidism. BMJ 1970; 4:145-148.
38. Nygaard B, Jensen EW, Kvetny J, Jarlov A, Faber J. Effect of combination therapy with thyroxine (T4) and 3,5,3’-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomized crossover study. Eur J Endocrinol 2009; 161(6):895-902.
39. Biondi B, Wartofsky L. Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism? J Clin Endocrinol Metab 2012; 97(7):2256-2271.
40. van der Deure WM, Appelhof BC, Peeters RP et al. Polymorphisms in the brain-specific thyroid hormone transporter OATP1C1 are associated with fatigue and depression in hypothyroid patients. Clin Endocrinol (Oxf) 2008; 69(5):804-811.
41. Panicker V, Saravanan P, Vaidya B et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab 2009; 94(5):1623-1629.
42. Peeters RP, van TH, Klootwijk W et al. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab 2003; 88(6):2880-2888.
43. Appelhof BC, Peeters RP, Wiersinga WM et al. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3’-triiodothyronine therapy. J Clin Endocrinol Metab 2005; 90(11):6296-6299.
